← Leaderboards
Christine Anne Pratilas
Sloan-Kettering Inst Can Research
$2,591,337
Attributed
$2,591,337
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $630K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,591,337 · 2
By mechanism
R01$1,725,555 · 1
K08$865,782 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Ping Chi$18,562,542
- David B. Solit$21,393,031
- Charles L Sawyers$34,701,646
- Samuel Singer$8,089,401
- Luis F Parada$23,930,635
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionCellsOncogenicSignal PathwayReceptor Protein-Tyrosine KinasesMeksMek InhibitionNeoplastic CellProgramsResponseTumorResistancePathway InteractionsClinical TrialsFeedbackGenetic TranscriptionCell LineCell GrowthEventEtv1 GeneEpidermal Growth Factor ReceptorErbb2 GeneEtv4 GeneExposure To
Grant awards (9)
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment$630,037
R01 · FY2025 · CA · contact PI
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment$541,365
R01 · FY2024 · CA · contact PI
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment$554,153
R01 · FY2023 · CA · contact PI
Feedback regulation and functional output of the RAS/RAF/MEK/MAPK pathway in huma$118,350
K08 · FY2013 · CA · contact PI
Feedback regulation and functional output of the RAS/RAF/MEK/MAPK pathway in huma$54,504
K08 · FY2013 · CA · contact PI
Feedback regulation and functional output of the RAS/RAF/MEK/MAPK pathway in huma$173,232
K08 · FY2012 · CA · contact PI
Feedback regulation and functional output of the RAS/RAF/MEK/MAPK pathway in huma$173,232
K08 · FY2011 · CA · contact PI
Feedback regulation and functional output of the RAS/RAF/MEK/MAPK pathway in huma$173,232
K08 · FY2010 · CA · contact PI
Feedback regulation and functional output of the RAS/RAF/MEK/MAPK pathway in huma$173,232
K08 · FY2009 · CA · contact PI